Diadema Partners’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-87,057
Closed -$907K – 190
2026
Q2
$907K Buy
+87,057
New +$645K 0.11% 106

Other funds holding RNAC

Diadema Partners's RNAC Position: Q3 2026 in Review

Diadema Partners sold out of Cartesian Therapeutics (RNAC) in Q3 2026, closing a stake of 87,057 shares — an estimated $907K sold.

Diadema Partners first reported a position in RNAC in Q2 2026 and held it in 1 quarter. The position peaked at $907K in Q2 2026. 99 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Diadema Partners reported no remaining Cartesian Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Diadema Partners sold 87,057 Cartesian Therapeutics shares in Q3 2026, an estimated $907K.
  • Diadema Partners first reported a position in Cartesian Therapeutics in Q2 2026 and held it in 1 quarter.
  • Diadema Partners's Cartesian Therapeutics position peaked at $907K in Q2 2026.
  • 99 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.